首页 | 本学科首页   官方微博 | 高级检索  
检索        

丹红注射液对急性心肌梗死PCI围手术期心功能和TIMI血流影响的Meta分析
引用本文:袁梦晨,高永红,王阶,赵步长,邢雁伟,李军,陈恒文,赵涛,赵超,王益民.丹红注射液对急性心肌梗死PCI围手术期心功能和TIMI血流影响的Meta分析[J].中国实验方剂学杂志,2020,26(1):178-183.
作者姓名:袁梦晨  高永红  王阶  赵步长  邢雁伟  李军  陈恒文  赵涛  赵超  王益民
作者单位:北京中医药大学 东直门医院, 中医内科学教育部和北京市重点实验室, 北京 100700;中国中医科学院 广安门医院, 北京 100053,北京中医药大学 东直门医院, 中医内科学教育部和北京市重点实验室, 北京 100700,中国中医科学院 广安门医院, 北京 100053,陕西步长制药有限公司, 西安 712000;山东丹红制药有限公司, 山东 菏泽 274000,中国中医科学院 广安门医院, 北京 100053,中国中医科学院 广安门医院, 北京 100053,中国中医科学院 广安门医院, 北京 100053,陕西步长制药有限公司, 西安 712000;山东丹红制药有限公司, 山东 菏泽 274000,陕西步长制药有限公司, 西安 712000;山东丹红制药有限公司, 山东 菏泽 274000,陕西步长制药有限公司, 西安 712000;山东丹红制药有限公司, 山东 菏泽 274000
基金项目:国家自然科学基金面上项目(81673847);国家重点研发计划重点专项(2018YFC1704901)
摘    要:目的:系统评价丹红注射液对急性心肌梗死(AMI)经皮冠状动脉介入治疗(PCI)围手术期心功能和心肌梗塞溶栓治疗(TIMI)血流分级的影响。方法:计算机检索CNKI,万方数据库,维普数据库,Pub Med,CBM,Web of Science,The Cochrane Library共7个数据库,全面采集在PCI围手术期应用丹红注射液治疗急性心梗的临床试验,采用Cochrane风险评价表进行文献质量评价,运用Revman 5.3软件进行Meta分析。结果:共纳入12个临床试验,包含1131例患者,其中丹红治疗组569例,对照组562例,结果显示在常规治疗的基础上加入丹红注射液治疗,患者的左室射血分数明显增高均数差(MD)=6.62,95%可信区间(CI)(4.91,8.34),P<0.00001],TIMI分级3级患者明显增多相对危险度(RR)=0.22,95%CI(0.12,0.41),P<0.00001],脑利钠肽水平明显降低MD=-151.86,95%CI(-247.00,-56.72),P=0.002]。结论:丹红注射液可以提高急性心梗PCI围手术期心功能和增加TIMI血流的分级。

关 键 词:急性心肌梗死  经皮冠状动脉介入治疗(PCI)  系统评价  左室射血分数(LVEF)  脑利钠肽(BNP)  心肌梗塞溶栓治疗(TIMI)  心功能
收稿时间:2019/11/8 0:00:00

Meta-Analysis for Effect of Danhong Injection on Cardiac Function and TIMI During Perioperative PCI in Acute Myocardial Infarction
YUAN Meng-chen,GAO Yong-hong,WANG Jie,ZHAO Bu-chang,XING Yan-wei,LI Jun,CHEN Heng-wen,ZHAO Tao,ZHAO Chao and WANG Yi-min.Meta-Analysis for Effect of Danhong Injection on Cardiac Function and TIMI During Perioperative PCI in Acute Myocardial Infarction[J].China Journal of Experimental Traditional Medical Formulae,2020,26(1):178-183.
Authors:YUAN Meng-chen  GAO Yong-hong  WANG Jie  ZHAO Bu-chang  XING Yan-wei  LI Jun  CHEN Heng-wen  ZHAO Tao  ZHAO Chao and WANG Yi-min
Institution:Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China;Guang''anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100053, China,Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China,Guang''anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100053, China,Buchang Pharmaceuticals Co. Ltd., Xi''an 712000, China;Shandong Danhong Pharmaceuticals Co. Ltd., Heze 274000, China,Guang''anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100053, China,Guang''anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100053, China,Guang''anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100053, China,Buchang Pharmaceuticals Co. Ltd., Xi''an 712000, China;Shandong Danhong Pharmaceuticals Co. Ltd., Heze 274000, China,Buchang Pharmaceuticals Co. Ltd., Xi''an 712000, China;Shandong Danhong Pharmaceuticals Co. Ltd., Heze 274000, China and Buchang Pharmaceuticals Co. Ltd., Xi''an 712000, China;Shandong Danhong Pharmaceuticals Co. Ltd., Heze 274000, China
Abstract:Objective: Evaluate the effects of Danhong injection for perioperative percutaneous coronary intervention (PCI) on cardiac function and thrombolysis in myocardial infarction (TIMI) in patients with acute myocardial infarction (AMI). Method: Computer retrieving CNKI, Wanfang database, VIP database, PubMed, CBM, Web of Science, The Cochrane Library, gathering Danhong injection in percutaneous coronary intervention perioperative application in the treatment of acute myocardial infarction clinic trials. The Cochrane risk evaluation is adopted to improve the quality of literature evaluation, with Revman 5.3 software for Meta-analysis. Result: Participants included in 12 clinic trials contains a total of 1 131 patients, including 569 patients in Danhong treatment and 562 patients in control group. The results showed that compared with conventional treatment, Danhong injection treated patients had LVEF increased obviouslymean difference (MD)=6.62, 95% confidence interval (CI) (4.91,8.34), P<0.000 01], the number of TIMI class 3 patients significantly increasedrelative risk (RR)=0.22, 95% CI(0.12,0.41), P <0.000 01], and BNP levels significantly decreasedMD=151.86, 95% CI (-247.00,-56.72), P=0.002]. Conclusion: Danhong injection can improve the function of acute myocardial infarction after percutaneous coronary intervention.
Keywords:acute myocardial infarction (AMI)  percutaneous coronary intervention (PCI)  Meta-analysis  left ventricular ejection fraction (LVEF)  brain natriuretic peptide (BNP)  thrombolysis in myocardial infarction (TIMI)  cardiac function
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号